ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/grp/volume-2019/8589402/figures/8589402.fig.004a.svgz" name="8589402.fig.004a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Antibody-mediated rejection (AMR)</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/grp/volume-2019/8589402/figures/8589402.fig.004b.svgz" name="8589402.fig.004b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Acute cellular rejection (ACR)</td></tr><tr class="fig-image" id="c"><td><object data="https://static.hindawi.com/articles/grp/volume-2019/8589402/figures/8589402.fig.004c.svgz" name="8589402.fig.004c" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(c) </b>1 yr overall survival</td></tr><tr class="fig-image" id="d"><td><object data="https://static.hindawi.com/articles/grp/volume-2019/8589402/figures/8589402.fig.004d.svgz" name="8589402.fig.004d" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(d) </b>3 yr overall survival</td></tr><tr class="fig-image" id="e"><td><object data="https://static.hindawi.com/articles/grp/volume-2019/8589402/figures/8589402.fig.004e.svgz" name="8589402.fig.004e" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(e) </b>5 yr overall survival</td></tr><tr class="fig-image" id="f"><td><object data="https://static.hindawi.com/articles/grp/volume-2019/8589402/figures/8589402.fig.004f.svgz" name="8589402.fig.004f" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(f) </b>1 yr graft survival</td></tr><tr class="fig-image" id="g"><td><object data="https://static.hindawi.com/articles/grp/volume-2019/8589402/figures/8589402.fig.004g.svgz" name="8589402.fig.004g" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(g) </b>3 yr graft survival</td></tr><tr class="fig-image" id="h"><td><object data="https://static.hindawi.com/articles/grp/volume-2019/8589402/figures/8589402.fig.004h.svgz" name="8589402.fig.004h" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(h) </b>5 yr graft survival</td></tr></table>

<div>Forest plot of postoperative long-term outcomes: (a) antibody-mediated rejection (AMR), (b) acute cellular rejection (ACR), (c) 1 yr overall survival, (d) 3 yr overall survival, (e) 5 yr overall survival, (f) 1 yr graft survival, (g) 3 yr graft survival, and (h) 5 yr graft survival.</div>

Gastroenterology Research and Practice

fig4

Figure 4

Figure 4: ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis 